Echo Therapeutics has made an advance in the product design of Symphony tCGM device and developed its electronic component package. The advance includes an initial 33% reduction in component size and improved architectural design as compared to the prototype electronic package of its earlier Symphony tCGM device.
Reportedly, Echo is developing a needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude SkinPrep System for transdermal drug delivery.
Echo Therapeutics said that it expects to complete the product development work for the entire Symphony tCGM System in the near-term and it anticipates entering new clinical trials shortly thereafter.
The completion of this electronic component package represents a major step towards custom integrated circuitry and product development completion. Echo believes that this accomplishment, coupled with the improved, one-piece biosensor that utilises new materials and an improved geometrical design, will improve sensor performance and decrease the size of the tCGM device from the size of the original prototype.
The final Symphony tCGM device is intended to be a cost-effective product that allows for advanced continuous glucose monitoring for patients and healthcare providers.
Patrick Mooney, chairman and CEO of Echo Therapeutics, said: “We believe that this technological improvement, combined with our new one-piece biosensor technology, will improve the accuracy of Symphony, while enhancing cost savings in manufacturing through our plans for future custom circuitry integration.”